Matches in SemOpenAlex for { <https://semopenalex.org/work/W2995537689> ?p ?o ?g. }
- W2995537689 endingPage "309" @default.
- W2995537689 startingPage "309" @default.
- W2995537689 abstract "This study evaluated nilotinib safety and its effects on biomarkers as a potential disease-modifying drug in Parkinson disease.To assess nilotinib effects on safety and pharmacokinetics and measure the change in exploratory biomarkers in patients with moderately severe Parkinson disease.This was a single-center, phase 2, randomized, double-blind, placebo-controlled trial with 300 patients approached in clinic; of these, 200 declined to participate, 100 were screened, 25 were excluded, and 75 were randomized 1:1:1 into placebo; nilotinib, 150-mg; or nilotinib, 300-mg groups. Recruitment started on May 17, 2017, and ended April 28, 2018, and follow-up ended August 10, 2019. Parkinson disease was confirmed according to the UK Brain Bank diagnostic criteria and symptoms were stabilized with use of optimal levodopa and/or dopamine agonists and other medications used in Parkinson disease.Nilotinib vs placebo, administered orally once daily for 12 months followed by a 3-month washout period.It was hypothesized that nilotinib is safe and can be detected in the cerebrospinal fluid, where it alters exploratory biomarkers via inhibition of Abelson tyrosine kinase and potentially improves clinical outcomes.Of the 75 patients included in the study, 55 were men (73.3%); mean (SD) age was 68.4 (8.2) years. Doses of 150 or 300 mg of nilotinib were reasonably safe, although more serious adverse events were detected in the nilotinib (150 mg: 6 [24%]; 300 mg: 12 [48%]) vs placebo (4 [16%]) groups. The 150-mg nilotinib group showed an increase in cerebrospinal fluid levels of the dopamine metabolites homovanillic acid (159.80nM; 90% CI, 7.04-312.60nM; P = .04) and 3,4-dihydroxyphenylacetic acid (4.87nM; 90% CI, 1.51-8.23nM; P = .01), and the 300-mg nilotinib group showed an increase in 3,4-dihydroxyphenylacetic acid (7.52nM; 90% CI, 2.35-12.69nM; P = .01). The nilotinib 150-mg but not the nilotinib 300-mg group demonstrated a reduction of α-synuclein oligomers (-0.04 pg/mL; 90% CI, -0.08 to 0.01 pg/mL; P = .03). A significant reduction of hyperphosphorylated tau levels was seen in the nilotinib 150-mg (-10.04 pg/mL; 90% CI, -17.41 to -2.67 pg/mL; P = .01) and nilotinib 300-mg (-12.05 pg/mL; 90% CI, -19.21 to -4.90 pg/mL; P = .01) groups.In this study, nilotinib appeared to be reasonably safe and detectable in the cerebrospinal fluid. Exploratory biomarkers were altered in response to nilotinib. Taken together, these data will guide the development of a phase 3 study to investigate the effects of nilotinib therapy in patients with Parkinson disease.ClinicalTrials.gov identifier: NCT02954978." @default.
- W2995537689 created "2019-12-26" @default.
- W2995537689 creator A5004586282 @default.
- W2995537689 creator A5009146393 @default.
- W2995537689 creator A5010233603 @default.
- W2995537689 creator A5017067396 @default.
- W2995537689 creator A5019985797 @default.
- W2995537689 creator A5045819980 @default.
- W2995537689 creator A5046518155 @default.
- W2995537689 creator A5048087226 @default.
- W2995537689 creator A5050219265 @default.
- W2995537689 creator A5059916599 @default.
- W2995537689 creator A5061427734 @default.
- W2995537689 creator A5066883241 @default.
- W2995537689 creator A5074186966 @default.
- W2995537689 creator A5075158659 @default.
- W2995537689 creator A5079485787 @default.
- W2995537689 creator A5081016350 @default.
- W2995537689 creator A5090295550 @default.
- W2995537689 creator A5090941234 @default.
- W2995537689 date "2020-03-01" @default.
- W2995537689 modified "2023-10-15" @default.
- W2995537689 title "Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease" @default.
- W2995537689 cites W1036529846 @default.
- W2995537689 cites W1527671059 @default.
- W2995537689 cites W1968942251 @default.
- W2995537689 cites W2013542960 @default.
- W2995537689 cites W2015808257 @default.
- W2995537689 cites W2017715011 @default.
- W2995537689 cites W2030180893 @default.
- W2995537689 cites W2031077231 @default.
- W2995537689 cites W2047724556 @default.
- W2995537689 cites W2050786534 @default.
- W2995537689 cites W2061356986 @default.
- W2995537689 cites W2078915251 @default.
- W2995537689 cites W2106255167 @default.
- W2995537689 cites W2110554184 @default.
- W2995537689 cites W2117376526 @default.
- W2995537689 cites W2137476611 @default.
- W2995537689 cites W2139910235 @default.
- W2995537689 cites W2141410612 @default.
- W2995537689 cites W2462137239 @default.
- W2995537689 cites W2808170870 @default.
- W2995537689 cites W2921582799 @default.
- W2995537689 cites W2924554494 @default.
- W2995537689 cites W4245861228 @default.
- W2995537689 cites W4247671298 @default.
- W2995537689 cites W4249414803 @default.
- W2995537689 cites W4251930300 @default.
- W2995537689 cites W4292528167 @default.
- W2995537689 doi "https://doi.org/10.1001/jamaneurol.2019.4200" @default.
- W2995537689 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6990742" @default.
- W2995537689 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31841599" @default.
- W2995537689 hasPublicationYear "2020" @default.
- W2995537689 type Work @default.
- W2995537689 sameAs 2995537689 @default.
- W2995537689 citedByCount "96" @default.
- W2995537689 countsByYear W29955376892020 @default.
- W2995537689 countsByYear W29955376892021 @default.
- W2995537689 countsByYear W29955376892022 @default.
- W2995537689 countsByYear W29955376892023 @default.
- W2995537689 crossrefType "journal-article" @default.
- W2995537689 hasAuthorship W2995537689A5004586282 @default.
- W2995537689 hasAuthorship W2995537689A5009146393 @default.
- W2995537689 hasAuthorship W2995537689A5010233603 @default.
- W2995537689 hasAuthorship W2995537689A5017067396 @default.
- W2995537689 hasAuthorship W2995537689A5019985797 @default.
- W2995537689 hasAuthorship W2995537689A5045819980 @default.
- W2995537689 hasAuthorship W2995537689A5046518155 @default.
- W2995537689 hasAuthorship W2995537689A5048087226 @default.
- W2995537689 hasAuthorship W2995537689A5050219265 @default.
- W2995537689 hasAuthorship W2995537689A5059916599 @default.
- W2995537689 hasAuthorship W2995537689A5061427734 @default.
- W2995537689 hasAuthorship W2995537689A5066883241 @default.
- W2995537689 hasAuthorship W2995537689A5074186966 @default.
- W2995537689 hasAuthorship W2995537689A5075158659 @default.
- W2995537689 hasAuthorship W2995537689A5079485787 @default.
- W2995537689 hasAuthorship W2995537689A5081016350 @default.
- W2995537689 hasAuthorship W2995537689A5090295550 @default.
- W2995537689 hasAuthorship W2995537689A5090941234 @default.
- W2995537689 hasBestOaLocation W29955376891 @default.
- W2995537689 hasConcept C126322002 @default.
- W2995537689 hasConcept C142724271 @default.
- W2995537689 hasConcept C170493617 @default.
- W2995537689 hasConcept C197934379 @default.
- W2995537689 hasConcept C204787440 @default.
- W2995537689 hasConcept C27081682 @default.
- W2995537689 hasConcept C2777413986 @default.
- W2995537689 hasConcept C2778375690 @default.
- W2995537689 hasConcept C2779134260 @default.
- W2995537689 hasConcept C2779734285 @default.
- W2995537689 hasConcept C42362537 @default.
- W2995537689 hasConcept C535046627 @default.
- W2995537689 hasConcept C71924100 @default.
- W2995537689 hasConcept C98274493 @default.
- W2995537689 hasConceptScore W2995537689C126322002 @default.
- W2995537689 hasConceptScore W2995537689C142724271 @default.
- W2995537689 hasConceptScore W2995537689C170493617 @default.